These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 26961969)
1. Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. Biswas N; Kuotsu K AAPS PharmSciTech; 2017 Feb; 18(2):349-357. PubMed ID: 26961969 [TBL] [Abstract][Full Text] [Related]
2. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan. Biswas N Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System. Nekkanti V; Wang Z; Betageri GV AAPS PharmSciTech; 2016 Aug; 17(4):851-62. PubMed ID: 26381913 [TBL] [Abstract][Full Text] [Related]
4. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. Chella N; Daravath B; Kumar D; Tadikonda RR Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887 [TBL] [Abstract][Full Text] [Related]
5. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan. Chella N; Tadikonda R Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274 [TBL] [Abstract][Full Text] [Related]
6. Development and optimization of press coated tablets of release engineered valsartan for pulsatile delivery. Shah S; Patel R; Soniwala M; Chavda J Drug Dev Ind Pharm; 2015; 41(11):1835-46. PubMed ID: 25721985 [TBL] [Abstract][Full Text] [Related]
7. Development of Nanocrystal Compressed Minitablets for Chronotherapeutic Drug Delivery. Sreeharsha N; Naveen NR; Anitha P; Goudanavar PS; Ramkanth S; Fattepur S; Telsang M; Habeebuddin M; Answer MK Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337109 [TBL] [Abstract][Full Text] [Related]
8. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Ige PP; Baria RK; Gattani SG Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990 [TBL] [Abstract][Full Text] [Related]
9. Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization. Prieto C; Evtoski Z; Pardo-Figuerez M; Hrakovsky J; Lagaron JM Mol Pharm; 2021 Aug; 18(8):2947-2958. PubMed ID: 34181413 [TBL] [Abstract][Full Text] [Related]
10. Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats. Amin MM; El Gazayerly ON; Abd El-Gawad NA; Abd El-Halim SM; El-Awdan SA Pharm Dev Technol; 2016 Dec; 21(8):909-920. PubMed ID: 26334707 [TBL] [Abstract][Full Text] [Related]
11. Development of Valsartan Floating Matrix Tablets Using Low Density Polypropylene Foam Powder: In vitro and In vivo Evaluation. Rahamathulla M; Saisivam S; Gangadharappa HV AAPS PharmSciTech; 2019 Jan; 20(1):35. PubMed ID: 30604045 [TBL] [Abstract][Full Text] [Related]
12. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. Gora S; Mustafa G; Sahni JK; Ali J; Baboota S Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379 [TBL] [Abstract][Full Text] [Related]
13. Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. Narayana L; Chella N; Kumar D; Shastri NR J Liposome Res; 2015; 25(4):325-33. PubMed ID: 25776099 [TBL] [Abstract][Full Text] [Related]
14. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435 [TBL] [Abstract][Full Text] [Related]
15. Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method. Shi-Ying J; Jin H; Shi-Xiao J; Qing-Yuan L; Jin-Xia B; Chen HG; Rui-Sheng L; Wei W; Hai-Long Y Chin J Nat Med; 2014 Jan; 12(1):71-80. PubMed ID: 24484600 [TBL] [Abstract][Full Text] [Related]
16. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. Jain S; Patel K; Arora S; Reddy VA; Dora CP Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292 [TBL] [Abstract][Full Text] [Related]
18. Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability. Ali HSM; Hanafy AF; Alqurshi A Int J Nanomedicine; 2019; 14():1893-1906. PubMed ID: 30936692 [TBL] [Abstract][Full Text] [Related]
19. [Preparation of valsartan nanosuspensions and its in vitro dissolution]. Li F; Song SS; Liu Y; Guo YX; Pan WS; Yang XG Yao Xue Xue Bao; 2013 Aug; 48(8):1312-8. PubMed ID: 24187842 [TBL] [Abstract][Full Text] [Related]
20. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. Morakul B; Suksiriworapong J; Chomnawang MT; Langguth P; Junyaprasert VB Eur J Pharm Biopharm; 2014 Nov; 88(3):886-96. PubMed ID: 25201298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]